Skip to main content

Advertisement

SpringerLink
Log in

KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

To investigate the impact of different KRAS mutations on treatment with the tyrosine kinase inhibitor sunitinib in SW48 colorectal cancer cell line variants.

Materials and methods

Isogenic SW48 KRAS wt, G12A, G12C, G12D, G12R, G12S, G12 V, and G13D cells were evaluated for ERK phosphorylation with and without EGF stimulation. In addition, the respective cell lines were tested for the effect of sunitinib on ERK/ELK phosphorylation, cell cycle, and cytotoxicity.

Results

Compared to KRAS wt cells, all KRAS mutant variants were associated with resistance to sunitinib treatment. In the MTT chemosensitivity assay, the grade of resistance was less pronounced in G13D and highest in G12A, G12C, and G12S mutant cells. The reduction in ERK phosphorylation due to treatment with sunitinib was highest in G12V (89 %) mutant cells and lowest in G12A (24 %) mutant cells. ELK phosphorylation was less decreased in all KRAS mutant variants compared to KRAS wt cells following sunitinib treatment. The grade of resistance appears to correlate with the individual KRAS-dependent intrinsic activation of ERK.

Conclusion

Our isogenic cell culture model suggests that KRAS mutations in SW48 colorectal cancer cells are linked to resistance to the multityrosine kinase inhibitor sunitinib. KRAS G13D mutant SW48 cells represented the KRAS subspecies with the lowest grade of resistance. Future studies will have to clarify whether KRAS can be used to guide sunitinib treatment or—in general—a treatment with a multityrosine kinase inhibitor in mCRC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  • Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471–478

    PubMed  CAS  Google Scholar 

  • Bazan V, Migliavacca M, Zanna I, Tubiolo C, Grassi N, Latteri MA, La Farina M, Albanese I, Dardanoni G, Salerno S, Tomasino RM, Labianca R, Gebbia N, Russo A (2002) Specific codon 13K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12K-ras mutations are associated with mucinous histotype. Ann Oncol 13:1438–1444

    Article  PubMed  CAS  Google Scholar 

  • Blesa JM, Pulido EG (2010) Colorectal cancer: response to sunitinib in a heavily pretreated colorectal cancer patient. Anticancer Drugs 21(Suppl 1):S23

    Article  PubMed  CAS  Google Scholar 

  • De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O’Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S (2010) Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304:1812–1820

    Article  PubMed  Google Scholar 

  • Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329–1338

    Article  PubMed  CAS  Google Scholar 

  • Di Nicolantonio F, Arena S, Gallicchio M, Zecchin D, Martini M, Flonta SE, Stella GM, Lamba S, Cancelliere C, Russo M, Geuna M, Appendino G, Fantozzi R, Medico E, Bardelli A (2008) Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proc Natl Acad Sci USA 105:20864–20869

    Article  PubMed  Google Scholar 

  • Doi Y, Yashiro M, Yamada N, Amano R, Noda S, Hirakawa K (2011) VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells. Ann Surg Oncol 19:2733–2743

    Google Scholar 

  • Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28:4697–4705

    Article  PubMed  CAS  Google Scholar 

  • Faivre S, Demetri G, Sargent W, Raymond E (2007) Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6:734–745

    Article  PubMed  CAS  Google Scholar 

  • Fang JY, Richardson BC (2005) The MAPK signalling pathways and colorectal cancer. Lancet Oncol 6:322–327

    Article  PubMed  CAS  Google Scholar 

  • Gattenlöhner S, Etschmann B, Riedmiller H, Müller-Hermelink HK (2009) Lack of KRAS and BRAF mutation in renal cell carcinoma. Eur Urol 55:1490–1491

    Article  PubMed  Google Scholar 

  • Hecht JR, Yoshino T, Mitchell EP, Dees MS, Countouriotis AM, Maneval EC, Kretschmar A (2010) A randomized, phase IIb study of sunitinib plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) versus bevacizumab plus mFOLFOX6 as first-line treatment for metastatic colorectal cancer (mCRC): Interim results. J Clin Oncol 28:15s (suppl; abstr 3532)

    Google Scholar 

  • Jeong WJ, Mo JH, Park MW, Choi IJ, An SY, Jeon EH, Ahn SH (2011) Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation. Cancer Biol Ther 12:458–465

    Article  PubMed  CAS  Google Scholar 

  • Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765

    Article  PubMed  CAS  Google Scholar 

  • Khan IF, Hirata RK, Russell DW (2011) AAV-mediated gene targeting methods for human cells. Nat Protoc 6:482–501

    Article  PubMed  CAS  Google Scholar 

  • Konishi H, Karakas B, Abukhdeir AM, Lauring J, Gustin JP, Garay JP, Konishi Y, Gallmeier E, Bachman KE, Park BH (2007) Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation. Cancer Res 67:8460–8467

    Article  PubMed  CAS  Google Scholar 

  • Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327–337

    PubMed  CAS  Google Scholar 

  • Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516–2524

    Article  PubMed  CAS  Google Scholar 

  • Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A (2009) Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract 205:858–862

    Article  PubMed  CAS  Google Scholar 

  • Odrowaz Z, Sharrocks AD (2012) ELK1 uses different DNA binding modes to regulate functionally distinct classes of target genes. PLoS Genet 8(5):e1002694

    Article  PubMed  CAS  Google Scholar 

  • O’Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC (2003) Cherrington JM.SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597–3605

    Article  PubMed  Google Scholar 

  • Peeters M, Douillard JY, van Cutsem E, Siena S, Zhang K, Williams R, Wiezorek J (2012) Mutant (MT) KRAS codon 12 and 13 alleles in patients (pts) with metastatic colorectal cancer (mCRC): assessment as prognostic and predictive biomarkers of response to panitumumab (pmab). J Clin Oncol Nov 26

  • Piscazzi A, Costantino E, Maddalena F, Natalicchio MI, Gerardi AM, Antonetti R, Cignarelli M, Landriscina M (2012) Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines. J Clin Endocrinol Metab 97:E898–906

    Google Scholar 

  • Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG, Bergsland EK, Haller DG, Lockhart AC, Rocha Lima CM, Huang X, DePrimo SE, Chow-Maneval E, Chao RC, Lenz HJ (2007) Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 25:4793–4799

    Article  PubMed  CAS  Google Scholar 

  • Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M, Slattery ML (2000) Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev 9:1193–1197

    PubMed  CAS  Google Scholar 

  • Scheffzek K, Ahmadian MR, Kabsch W, Wiesmüller L, Lautwein A, Schmitz F, Wittinghofer A (1997) The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 277(5324):333–338

    Article  PubMed  CAS  Google Scholar 

  • Seeburg PH, Colby WW, Capon DJ, Goeddel DV, Levinson AD (1984) Biological properties of human c-Ha-ras1 genes mutated at codon 12. Nature 312(5989):71–75

    Article  PubMed  CAS  Google Scholar 

  • Ströbel P, Bargou R, Wolff A, Spitzer D, Manegold C, Dimitrakopoulou-Strauss A, Strauss L, Sauer C, Mayer F, Hohenberger P, Marx A (2010) Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br J Cancer 103:196–200

    Article  PubMed  Google Scholar 

  • Szymańska K, Moore LE, Rothman N, Chow WH, Waldman F, Jaeger E, Waterboer T, Foretova L, Navratilova M, Janout V, Kollarova H, Zaridze D, Matveev V, Mates D, Szeszenia-Dabrowska N, Holcatova I, Bencko V, Le Calvez-Kelm F, Villar S, Pawlita M, Boffetta P, Hainaut P, Brennan P (2010) TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern Europe. Cancer Lett 293:92–98

    Article  PubMed  Google Scholar 

  • Takeuchi A, Eto M, Shiota M, Tatsugami K, Yokomizo A, Kuroiwa K, Itsumi M, Naito S (2012) Sunitinib enhances antitumor effects against chemotherapy-resistant bladder cancer through suppression of ERK1/2 phosphorylation. Int J Oncol 40:1691–1696

    PubMed  CAS  Google Scholar 

  • Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E (2012) Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 30:3570–3577

    Google Scholar 

  • Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D’Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417

    Article  PubMed  Google Scholar 

  • Zietsch J, Ziegenhagen N, Heppner FL, Reuss D, von Deimling A, Holtkamp N (2010) The 4q12 amplicon in malignant peripheral nerve sheath tumors: consequences on gene expression and implications for sunitinib treatment. PLoS ONE 5:e11858

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

DPM received a research grant from the University of Munich for this project (FöFoLe-number 745) and thanks Prof. Dr. W. Hiddemann for his support. Horizon Discovery Ltd., Cambridge, CB25 9TL, Great Britain, kindly supported this project by providing the isogenic SW48-based cell lines on an academic research basis.

Conflict of interest

The authors declare no possible conflicts of interest with regard to the present paper.

Author information

Authors and Affiliations

  1. Department of Medicine III, University Hospital Grosshadern, University of Munich, Munich, Germany

    D. P. Modest, V. Heinemann & S. Stintzing

  2. Department of Surgery, University Hospital Grosshadern, University of Munich, Munich, Germany

    P. Camaj, B. Schwarz, S. Gamba, C. Haertl, S. Primo & C. J. Bruns

  3. Institute of Pathology, University of Munich, Munich, Germany

    A. Jung

  4. Institute of Medical Informatics, Biometry and Epidemiology, University of Munich, Munich, Germany

    R. P. Laubender

Authors
  1. D. P. Modest
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Camaj
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V. Heinemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. Schwarz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R. P. Laubender
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. Gamba
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C. Haertl
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S. Stintzing
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S. Primo
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. C. J. Bruns
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. P. Modest.

Additional information

P. Camaj and D. P. Modest contributed equally to this manuscript.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Modest, D.P., Camaj, P., Heinemann, V. et al. KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer. J Cancer Res Clin Oncol 139, 953–961 (2013). https://doi.org/10.1007/s00432-013-1401-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-013-1401-9

Keywords

Search

Navigation